24th May, 2021, Vishakhapatnam, AP, India

The current pandemic has brought more than US$21 trillions losses creating a global political economic and financial crises, we as a start up company have identified potential lead molecules with InSilico docking studies

In-Silico studies exhibits a potent protein inhibitors with potent anti-viral activity against SARS-CoV-2

  • InSilico Results as a highly potential lead molecules for SARS-CoV-2

  • Comparison of InSilico Studies with other drugs in market shows better potential

  • Looking for strategic JV partners for clinical trials and global approvals


Sadhgama Biosciences Private Limited is in the process of filing a patent for 6 novel potential molecules that fight against novel corona virus 2019. The company developed 6 potential molecules on the basis of Insilico studies &  results. Initially, virtual screening studies were performed and selected few molecules out of which 6 molecules were selected. The molecules were selected on the basis of molecular modelling and molecular docking studies against corona virus 2019. Further studies to be carried out in  cell line activity and animal studies with interested Strategic JV partners for clinical trials and global regulatory approvals. Our molecules showed good binding energies than the drugs currently used like Remdesivir, Fabiflu etc., According to molecular docking studies novel molecules are more potent than the drugs than existing drugs for treatment of SARS-Cov-2.


About Sadhgama:

M/s Sadhgama Biosciences Pvt. Ltd. has been instrumental in acquiring advanced skills in Bioinformatics and Drug Discovery and exploring InSilico methodology of discovering potential target drugs for viral and bacterial diseases.  Sadhgama Biosciences Pvt. Ltd. is  a startup company with 18 years of hands on experience in the field of molecular modelling, ligand and structure based drug designing besides vast experience in developing synthetic compound databases found passion to discover new drug molecules with potential disease targets towards TB, Cancer, Malaria, AIDS and Alzheimer's etc. for human diseases, Aquaculture for  control of Vibrios, EHP and YHV which is effecting Global production of around 50%..

Media & Investor Contact:
+91 9059658876